Selenium/vit E "do not cut prostate cancer risk"

22 December 2008

Findings from one of the largest cancer chemoprevention trials ever conducted suggest that selenium and vitamin E taken alone or in combination for an average of five and a half years does not prevent prostate cancer.

A team of researchers, coordinated by the USA's Southwest Oncology Group and led by scientists at the University of Texas MD Anderson Cancer Center and Cleveland Clinic, analyzed data gathered from 5,533 participants.

In the randomized, placebo-controlled and double-blind trial, 4.43% of those on placebo were diagnosed with prostate cancer during the five-year duration of the study, while this was 4.56% both for the group taking selenium or selenium plus vitamin E and 4.93% for participants taking vitamin E alone.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight